PARIS, May 15 Sanofi-aventis-patent
PARIS, May 15 /PRNewswire-FirstCall/ -- Sanofi-aventis announced that the
U.S. Court of Appeals for the Federal Circuit has affirmed the February 8,
2007 decision by the U.S. District Court for the Central District of
California in the sanofi-aventis Lovenox(R) patent infringement suit against
Amphastar and Teva.
As a result of the Court of Appeals' ruling, the U.S. Lovenox(R) patent is
deemed to be unenforceable.
Sanofi-aventis is considering all its legal options.
While several generic manufacturers have requested marketing approval from
the FDA for their products alleged to be generic versions of Lovenox(R),
sanofi-aventis has not learned of any FDA approval of these requests.
About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers,
develops and distributes therapeutic solutions to improve the lives of
everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York
(NYSE: SNY).
Forward Looking Statements
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include financial projections and estimates and their underlying assumptions,
statements regarding plans, objectives, intentions and expectations with
respect to future events, operations, products and services, and statements
regarding future performance. Forward-looking statements are generally
identified by the words "expects," "anticipates," "believes," "intends,"
"estimates," "plans" and similar expressions. Although sanofi-aventis'
management believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and uncertainties,
many of which are difficult to predict and generally beyond the control of
sanofi-aventis, that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the forward-
looking information and statements. These risks and uncertainties include
those discussed or identified in the public filings with the SEC and the AMF
made by sanofi-aventis, including those listed under "Risk Factors" and
"Cautionary Statement Regarding Forward-Looking Statements" in
sanofi-aventis' annual report on Form 20-F for the year ended December 31,
2007. Other than as required by applicable law, sanofi-aventis does not
undertake any obligation to update or revise any forward-looking information
or statements.
CONTACT: Jean-Marc Podvin
sanofi-aventis
+331-53-77-4223
jeanmarc.podvin@sanofi-aventis.com
SOURCE sanofi-aventis
